Wegovy, Zepbound Costs Surge
This is a the United States news story, published by USA Today, that relates primarily to Wegovy news.
the United States news
For more the United States news, you can click here:
more the United States newsWegovy news
For more Wegovy news, you can click here:
more Wegovy newsdrug discoveries news
For more drug discoveries news, you can click here:
more drug discoveries newsUSA Today news
For more news from USA Today, you can click here:
more news from USA TodayAbout the Otherweb
Otherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about
weight loss medication Wegovy. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest weight loss drug Zepbound news, new weight loss drugs news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
Weight loss drugs WegovyUSA Today
•Health
Health
Weight loss drugs Wegovy and Zepbound strain budgets amid skyrocketing copays
82% Informative
Weight loss drugs Wegovy and Zepbound will be downgraded to a different coverage tier on her insurance plan.
Blue Cross Blue Shield is changing coverage for GLP-1 drugs, which will cost $ 713 per month.
Only about one-third of those prescribed these drugs remain on them for a year or more.
Insurance coverage for weight loss "is the biggest barrier we have in the United States ," Dr. Angela Fitch says.
In 2024 , 44% of all large employers covered GLP-1 drugs for obesity, up from 41% last year .
Employers impose conditions before employees can qualify for the drugs, such as obtaining authorization before filling a prescription.
The high list prices of these new weight loss drugs are costly for taxpayer-funded health programs.
Some lawmakers have called for more efforts to target drugmakers prices.
In an Oct. 17 letter, the FDA told the Alliance for Pharmacy Compounding that it would not take any immediate enforcement action.
Still, the uncertainty worries consumers like Bonello who rely on these compounded drugs.
VR Score
83
Informative language
82
Neutral language
45
Article tone
semi-formal
Language
English
Language complexity
47
Offensive language
possibly offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
short-lived
External references
12
Source diversity
11
Affiliate links
no affiliate links